Coverage

In a recent conversation with Matt Pillar, Host of the Business of Biotech podcast, our CEO and co-founder, Yochi Slonim, discussed how Anima's proprietary mRNA Lightning Platform, which combines the power of AI with mRNA biology visualizations to transforming the industry’s approach to drug discovery through the identification of potential small molecule drugs, and optimize RNA-based drugs and vaccine. To learn more, listen to the full episode here.

In a recent Labiotech article, Anima was featured as a groundbreaking company leading the mRNA revolution in biotech. Read the full piece to learn more about how our mRNA Lightning Platform harnesses the power of AI in combination with mRNA biology to identify small molecules, transforming the industry’s approach to drug discovery.

In a recent discussion with Drug Discovery World, CEO, and Co-founder, Yochi Slonim shares insights into the emergence of mRNA in drug discovery and development, exploring potential and future opportunies for mRNA-based therapies.

Anima Biotech's new drug candidate for IPF treatment shows superior results in preclinical trials. The drug, which uses a unique mechanism to disrupt fibrosis development, further validates the company's approach of combining AI and mRNA biology for drug discovery.

AI drug discovery company Anima Biotech has revealed encouraging preclinical results for its drug candidate addressing Idiopathic Pulmonary Fibrosis (IPF), an age-related condition in which the lungs become scarred and makes breathing difficult. The drug, designed to disrupt the transformation of fibroblasts into fully differentiated myofibroblasts, operates through a novel mRNA biology mechanism of action.

In a recent article in Drug Target Review, our CEO and co-founder Yochi Slonim, discusses how Anima is forging a new path forward in drug and target discovery by bringing AI to mRNA biology.

In a recent roundtable article in Pharma’s Almanac, our CEO and co-founder, Yochi Slonim, discusses the areas of the pharmaceutical industry he’s excited to see more adoption of AI and machine learning in, specifically highlighting the vast potential of AI’s role in drug discovery.

In a recent article in Labiotech, our CEO and co-founder, Yochi Slonim, discusses the evolution of mRNA technology in drug discovery and provides his insight on what the future holds for the mRNA biology space including small molecule mRNA drugs and how they could revolutionize the treatment of once considered “undruggable” diseases.

In a recent Nature Biotechnology "News in brief" article titled "Big pharma craves slice of AI-based RNA drug discovery," Anima was featured as a significant player in the field. The article commended Anima's innovative approach, which not only identifies promising small-molecule mRNA drugs but also provides a detailed understanding of their mechanisms of action by integrating cutting-edge AI technology.

Read our CEO and co-founder Yochi Slonim’s insights on the importance of collaboration and partnership in biopharma in a recent Labiotech article. With three big pharma collaborations for Anima, his expert understanding of the space makes for sound advice.

AbbVie has agreed to discover and develop mRNA biology modulators for three targets in oncology and/or immunology by applying Anima Biotech’s messenger RNA-based mRNA Lightning platform, through an up to $582 million collaboration announced by the companies.

A USD $42 million collaboration between AbbVie and Anima Biotech aims to leverage the latter’s mRNA Lightning technology platform to enhance therapeutic development programs in oncology and immunology.

With pandemics and global health concerns in the headlines, it is good to know there are companies like Anima Biotech leveraging advanced technology to accelerate pharma solutions. Under the leadership of Co-founder and CEO Yochi Slonim, the team at Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action. If you do not understand what this means, take a listen as we promise you will be fascinated and learn something new.

AbbVie and Anima Biotech will develop mRNA biology modulators across three targets in oncology and immunology in a collaboration worth up to $580m.

AbbVie Inc. on Tuesday said it plans to work with privately held Anima Biotech to discover and develop mRNA biology modulators for three targets across oncology and immunology.

Privately-held USA-based small-molecule mRNA translation specialist Anima Biotech has entered into other major collaboration, this time with US pharma major AbbVie (NYSE: ABBV), which is potentially worth more than $580 million and is aimed at discovering and developing drugs that modulate mRNA biology for three targets in cancer or immune disorders.

Anima will receive $42M up front, ~$540M in option fees and R&D milestones across 3 targets & is also eligible for commercial milestones along with royalties on net sales

Anima Biotech will receive an upfront payment of $42 million from AbbVie. Another $540 million is on the line in the form of option fees and research and development milestones for the discovery and development of mRNA biology modulators across three targets in oncology and immunology using the company’s Lightning platform. Commercial milestones and tiered royalties could also lead to more payouts for Anima.

AbbVie has joined Anima Biotech’s star-studded roster of partners, paying $42 million upfront to work with the biotech on small molecule mRNA drugs against three “undruggable” targets in oncology and immunology. 

AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets in oncology and immunology. 

The latest partner for New Jersey-based Anima Biotech Inc. is AbbVie Inc. (NYSE:ABBV), which will draw on the privately held biotech's phenotypic screening and mRNA discovery expertise in a three-target deal spanning oncology and immunology.

AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.

The discovery of mRNA biology modulators will be based on Anima's mRNA Lightning platform. The collaboration offers AbbVie exclusive rights to license and further develop and commercialize the programs.

AbbVie Inc. (ABBV), and Anima Biotech (Anima) Tuesday announced a collaboration in mRNA biology modulators for three targets across Oncology and Immunology. As per the agreement, Anima will receive an upfront payment of $42 million with the potential for further milestones and royalties and up to $540 million in option fees and R&D milestones.

Since the advent of COVID-19 mRNA vaccines, the space has steadily grown hotter, a situation on which Anima Biotech Inc. has capitalized by way of a potential $580 million-plus deal with Abbvie Inc. to deploy mRNA biology modulators for three targets across oncology and Immunology.

AbbVie has collaborated with Anima Biotech for the discovery and development of mRNA biology modulators against three oncology and immunology targets. The collaboration will use the mRNA Lightning platform from Anima and AbbVie‘s oncology and immunology expertise to discover new mRNA biology modulators against the targets.

AbbVie Inc. on Tuesday said it plans to work with privately held Anima Biotech to discover and develop mRNA biology modulators for three targets across oncology and immunology.

AbbVie (NYSE:ABBV) has partnered with New Jersey-based Anima Biotech to co-develop mRNA-based candidates against three targets in oncology and immunology, the companies announced on Tuesday.

AbbVie and Amina Biotech have announced their collaboration for the discovery and development of mRNA biology modulators focusing on three oncology and immunology targets.

AbbVie and Anima Biotech entered a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.

Anima Biotech will get a $42m upfront payment with the possibility of further payments towards research and development milestones, royalties on net sales, and option fees.

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and immunology.

AbbVie and Anima Biotech (Anima) have entered into a collaboration for the discovery and development of mRNA biology modulators against three oncology and immunology targets, the companies announced.

Our CEO and co-founder, Yochi Slonim, was featured in BioPharmaTrend. In this Q&A, Yochi shares his entrepreneurial journey and how Anima thrives at the intersection of software and biology to identify small molecule modulators of mRNA translation.

Our Co-founder and CEO, Yochi Slonim recently shared with Pharma’s Almanac his entrepreneurial journey, the genesis of Anima and how we are advancing mRNA Lightning, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action.

Our CEO, Yochi Slonim discusses his entrepreneurial journey, the genesis of Anima Biotech and how we combine high-scale phenotypic screening with AI mRNA image analysis to discover selective mRNA small molecule drugs and rapidly elucidate their mechanisms of action on the Biotech 2050 Podcast with Alok Tayi, Ph.D. and Rahul Chatuverdi. Each week, Biotech2050 brings in experts across biotech to learn more about how their work “disrupts” the industry and evokes change.

Anima’s CEO and co-founder, Yochi Slonim is featured in the latest article from PM360 available today. Yochi shares his insight on what it takes to stand out and attract partnerships in biotech, overcoming hurdles in order to have successful collaborations and how COVID-19 and the virtual workplace has changed the landscape of partnerships. 

Our founder and CEO, Yochi Slonim, was featured in the BioBoss podcast with John Simboli. BioBoss showcases founders and CEOs from today’s most innovative biotech companies. You’ll hear Yochi discuss how he arrived in biotech, his thoughts on leading a cutting-edge biotech company, and how Anima combines AI and biology into our novel pipeline for developing small molecule mRNA translation modulators to target the undruggable. 

Anima Biotech Co-founder and CEO, Yochi Slonim, was featured among 12 biopharma executives in an article by Heather McKenzie for BioSpace where he provided insight on what will be the hottest therapeutic area in 2022. Anima’s unique mRNA Lightning platform will serve as a catalyst to uncover a “drug mine” of novel therapies that will continue to build in momentum in 2022 as the pharmaceutical industry continues to engage in open and willing partnerships related to the space

For the computer expert/CEO of Anima, Yochi Slonim, it’s all the same – lots of instructions and lots of code. It could be code for AI, it could be codons for the translation of proteins. With the elucidation of unique codon pairings by mRNA Lightning, Slonim can turn expression on or off, or up or down, depending on the therapeutic need, like say, in CNS disorders. Eli Lilly has taken notice. So has Takeda. You might want to give a listen…

Leveraging mRNA to develop game-changing medicines has already been demonstrated with the development of vaccines to tackle the COVID-19 pandemic. In this article, BioSpace goes beyond the currently available vaccines to discuss the potential mRNA-based therapeutics hold in fostering the next wave of therapeutics for many diseases or conditions that cannot be treated otherwise.

In this story, Anima Biotech Co-Founder and CEO, Yochi Slonim, shares his philosophies about what it takes to be an optimal collaborator in the life sciences industry. From his beginnings as a serial entrepreneur in the world of high tech, Mr. Slonim shared how his professional path led him to co-found Anima and how the company is focused both on expanding its internal pipeline while simultaneously identifying large pharma/biotech companies that share the same vision as Anima in developing potentially game-changing small molecule drugs for a variety of hard-to-treat diseases.

The development of mRNA therapies is allowing drug developer to pursue targets once considered undruggable. Anima Biotech has developed a platform that allows it to use small molecule that selectively control mRNA and can decrease or increase the translation of proteins. The approach has broad applicability as evidenced by the company’s pipeline, which includes experimental therapies for oncology, neurology, infectious disease, and fibrosis. We spoke to Yochi Slonim, CEO of Anima, about the company platform technology, how it can modulate the expression of proteins, and how it is leveraging its technology through partnerships with some of the world’s largest pharmaceutical companies.

In this article, Anima Biotech Co-Founder and CEO, Yochi Slonim, discusses the journey to their up-to $2.4 billion collaboration with Takeda Pharmaceuticals to develop small molecule mRNA translation modulators in Neuroscience. From his background as a serial entrepreneur to the development of Anima’s proprietary Translation Control Therapeutics Platform, the article provides context for the success of the company’s mRNA-focused drug discovery pipeline.

The maximum size of the Anima deal could swell to more than $2 billion. (Takeda)
Takeda has teamed up with Anima Biotech to discover mRNA translation modulators. The Japanese drugmaker is set to pay up to $120 million in upfront fees and preclinical research milestones to work with Anima on the treatments for genetically defined neurological diseases.

Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.

Anima Biotech and Takeda Pharmaceutical are collaborating to discover and develop mRNA translation modulators for neurological diseases. According to the deal, Anima will discover mRNA translation modulators using its Translation Control Therapeutics platform to develop a new class of medicines for genetically-defined neurological diseases.

Takeda already has one shot in Huntington’s, via a 2018 deal with Wave Life Sciences. The Japanese company put down another marker in the disease today by teaming up with the private Israeli company Anima Biotech.

Anima Biotech, a company focused on the discovery of small molecule drugs that selectively control mRNA translation, has entered into a strategic collaboration with Takeda Pharmaceutical to discover and develop a new class of medicines for genetically defined neurological diseases.

Small-molecule mRNA translation expert Anima Biotech Inc. has landed a significant new preclinical research deal with Takeda Pharmaceutical Co. Ltd., covering as many as six programs for genetically-defined neurological diseases. The deal starts with $120 million for Anima up front, but altogether, the two-part collaboration could hold as much as $2.3 billion in clinical and commercial milestone payouts for the company, providing substantial support for its internal pipeline, Anima’s co-founder and CEO Yochi Slonim told BioWorld.

Takeda has signed a collaboration with Anima Biotech, covering up to six different programs with promises of up to $2.3 billion in milestones. Under the deal, Anima will initially conduct preclinical research for Huntington’s disease, as well as two other small molecule candidates.

Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.

Anima Biotech said that it reached a strategic collaboration with Takeda Pharmaceutical Company Limited to discover and develop a new class of medicines for genetically-defined neurological diseases.

As per the terms of the deal, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets.

In this Q&A interview with our CEO, Yochi Slonim, senior editor Andrew Matthius of PM360 highlights how Anima’s approach of discovering small molecules that can selectively control mRNA translation to treat diseases is shifting the paradigm in how we think about drug discovery and development. In this piece, Mr. Slonim shares the beginnings of Anima, the current state of mRNA drug development given the COVID-19 pandemic and how Anima’s approach is unique in that they are not discovering small molecules to bind to mRNA, but rather targeting the translation of these proteins.  

In this review with fellow top executives from the biotechnology space, our CEO Yochi Slonim speaks about what the industry has learned from this past year and his predictions for 2021. Mr. Slonim describes the biggest new source of drugs and Anima's approach to open up this goldmine of novel targets by finding small molecules that can bind to the proteins that regulate protein translation rather than drugging mRNA or proteins directly.

In the open access Elsevier journal, Drug Discovery Today, experts from Anima highlight mRNA translation regulatory mechanisms and potential drug-intervention targets. Underlying Anima’s approach is a new scientific rationale of translation regulation, which consequently has led to this new target space. In this article, the authors take a deep dive into how Anima’s unique discovery platform is able to identify selective small molecule drugs that affect translation of specific proteins, which has enabled targeting of proteins that may have been previously deemed, undruggable.

In this interview with senior science writer and editor, Laura Lansdowne of Technology Networks, our co-founder and CEO Yochi Slonim discusses Anima Biotech’s background, technology platform, and our strategy against previously deemed ‘undruggable’ targets to help underserved patients with hard-to-treat diseases.

In this article by Nikki Withers, our CEO Yochi Slonim discusses how Anima’s drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease leveraging FRET light pulses to visualize mRNA translation from within ribosomes. This approach enables the discovery of small molecules that modulate the translation of a target protein as an entirely novel target space to aid in the treatment of undruggable diseases

Anima biotech was named Startup City’s 15 Most Promising Biotech Startups of 2019. In the feature, our CEO Yochi Slonim discusses how Anima’s drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease. This piece also examines the current mRNA therapeutics space.

Anima Biotech Inc CEO Yochi Slonim caught up with Proactive at the 2019 BIO Investor Forum in San Francisco. 

Slonim updated investors on its Translation Control Therapeutics platform and reflected on the company's partnership with Eli Lilly and Company.

In this interview with Gail Dutton in Genetic Engineering & Biotechnology News, our CEO Yochi Slonim discusses Anima Biotech’s novel strategy and approach to the discovery and development of new small molecule drugs that target and control the process of mRNA translation into proteins.

In this deeper dive into how biopharmaceutical companies are approaching translational medicine, our CEO Yochi Slonim and other experts in the industry discuss novel targets in drug discovery and how to increase the number of drugs that can be successfully brought to market.

In this article by Chelsea Weidman Burke, our CEO Yochi Slonim discusses how Anima’s own drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease. This piece also examines the current mRNA therapeutics space.

This piece written by Cath O’Driscoll discusses Anima’s new approach to the discovery of small molecule drugs to target previously hard to treat diseases and could lead to safer, more versatile treatments.

Coverage from a panel during the 2019 BIO convention features the leaders and founders of emerging platform companies including our own CEO Yochi Slonim. This article reviews what makes platform players different from other biopharma ventures and how Anima Biotech’s own drug discovery platform works to identify new small molecules that affect protein synthesis.

This video interview with Mike Ward (Pharma Intelligence) at BIO-Europe Spring 2019, showcases Anima Biotech’s novel approach to discover small molecule drugs that regulate and control the process of mRNA translation into proteins. 

In this roundtable review, our CEO Yochi Slonim answers the question “What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?” Mr. Slonim describes more traditional approaches to drug discovery and how Anima is opening up an entirely different space of novel targets by finding small molecules that can bind to the proteins that regulate protein translation rather than drugging mRNA or proteins directly.

This feature by Lauren Martz, Associate Editor of BioCentury, covers how Anima Biotech is leveraging its Translation Control Therapeutics platform to purse novel targets of mRNA translation regulators in order to develop tissue selective small molecule drugs.

In this interview with our CEO Yochi Slonim, Mark Terry, contributing writer to BioSpace, examines Anima Biotech’s unique approach to mRNA therapeutics and its high throughput screening technology platform to identify small molecules that can decrease or increase mRNA translation into proteins.

In this video, learn how Anima Biotech’s platform can visualize the protein synthesis process allowing scientists to gain insights into the mechanisms of disease and discover new drugs that control protein translation.

In this video interview with Tim Luker, Senior Director, Emerging Technology & Innovation at Eli Lilly & Co., describes what the collaboration with Anima Biotech and the potential of Anima’s Translation Control Therapeutics technology means to the future of drug discovery at Eli Lilly.

This company profile, written by Jo Shorthouse, establishes Anima Biotech as a leader in the translation biology space with its technology for the discovery and development of small molecule drugs that control and regulate protein synthesis.

Eli Lilly is teaming up with Anima Biotech in collaboration to discover and develop translation inhibitors for several protein targets.

Israel-based Anima will receive an upfront payment of $30 million and $14 million for research, but could potentially get as much as $1.05 billion in milestones

Eli Lilly $LLY is commissioning a small team in New Jersey to implement its unusual approach to drug discovery on a few of Lilly’s targets, paying out $30 million in an upfront fee plus some cash to get the research started.

Anima Biotech, based in Bernardsville, New Jersey, inked a discovery and development deal with Eli Lilly and Co. that has the potential to exceed $1 billion.

Anima Biotech has signed a deal with Eli Lilly potentially worth more than $1 billion in biobucks as the pair seeks to work on the biotech’s translation inhibitors.

In a company examination, this article describes the therapeutic potential of Anima Biotech’s Translation Control Therapeutics technology in the discovery of small molecules that control protein translation.